Evidence map›Paper›PMID 38733535›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2024

The Effects of Fingolimod (FTY720) on Leukocyte Subset Circulation cannot be Behaviourally Conditioned in Rats.

Marie Jakobs, Tina Hörbelt-Grünheidt, Martin Hadamitzky, Julia Bihorac, Yasmin Salem, Stephan Leisengang, Uwe Christians, Björn Schniedewind, Manfred Schedlowski, Laura Lückemann

Abstract read
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marie JakobsInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany. Marie.Jakobs@uk-essen.de.
Tina Hörbelt-GrünheidtInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Martin HadamitzkyInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Julia BihoracInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Yasmin SalemInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Stephan LeisengangInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Uwe ChristiansiC42 Clinical Research and Development, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Björn SchniedewindiC42 Clinical Research and Development, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Manfred SchedlowskiInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.
Laura LückemannInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro- & Behavioral Sciences, University Hospital Essen, 45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suppression of immune functions can be elicited by behavioural conditioning using drugs such as cyclosporin A or rapamycin. Nevertheless, little is known about the underlying mechanisms and generalisability of this phenomenon. Against this background, the present study investigated whether the pharmacological properties of fingolimod (FTY720), an immunosuppressive drug widely applied to treat multiple sclerosis, can be conditioned in rats by means of taste-immune associative learning. For this purpose, a conditioned taste avoidance paradigm was used, pairing the presentation of a novel sweet drinking solution (saccharin or sucrose) as conditioned stimulus (CS) with therapeutically effective doses of FTY720 as unconditioned stimulus (US). Subsequent re-exposure to the CS at a later time point revealed that conditioning with FTY720 induced a mild conditioned taste avoidance only when saccharin was employed as CS. However, on an immunological level, neither re-exposure with saccharin nor sucrose altered blood immune cell subsets or splenic cytokine production. Despite the fact that intraperitonally administered FTY720 could be detected in brain regions known to mediate neuro-immune interactions, the present findings show that the physiological action of FTY720 is not inducible by mere taste-immune associative learning. Whether conditioning generalises across all small-molecule drugs with immunosuppressive properties still needs to be investigated with modified paradigms probably using distinct sensory CS. Moreover, these findings emphasize the need to further investigate the underlying mechanisms of conditioned immunomodulation to assess the generalisability and usability of associative learning protocols as supportive therapies in clinical contexts.

Indexed as

Fingolimod HydrochlorideImmunosuppressive AgentsAnimalsAvoidance LearningConditioning, ClassicalLeukocytesMalePropylene GlycolsRatsRats, WistarSaccharinTasteFingolimod HydrochlorideImmunosuppressive AgentsPropylene GlycolsSaccharinConditioned Taste AvoidanceFingolimodImmunosuppressionTaste-immune Associative Learning

Identifiers

PMID38733535
PMCPMC11088542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.